PROM1 and colorectal carcinoma: To determine whether GO-Y030 may have therapeutic potential for clinical colorectal carcinoma treatment, we further tested GO-Y030 against ALDH+/CD133+ cells isolated from the SW480 and HCT-116 colon cancer cells in NOD/SCID mice xenograft models in vivo.